Matinas BioPharma Reports 2016 Third Quarter Financial Results And Provides Corporate Update
11/15/2016 9:22:44 AM
BEDMINSTER, N.J., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, today announced its financial results for the quarter ended September 30, 2016.
The Company also reviewed the progress of its lead anti-infective product in development, MAT2203, an orally-administered, encochleated formulation of amphotericin B (a broad spectrum fungicidal agent), and the development plans for MAT2501, an orally administered, encochleated formulation of the broad spectrum aminoglycoside antibiotic amikacin to treat gram-negative bacterial infections and other intracellular bacterial infections.
comments powered by